Astria Therapeutics logo

Astria TherapeuticsNASDAQ: ATXS

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

25 June 2015

Next earnings report:

04 March 2025

Last dividends:

N/A

Next dividends:

N/A
$540.64 M
-41%vs. 3y high
67%vs. sector
-vs. 3y high
-vs. sector
-95%vs. 3y high
60%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 21:02:21 GMT
$9.58-$0.15(-1.54%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ATXS Latest News

Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
businesswire.com13 November 2024 Sentiment: POSITIVE

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. “We had another strong quarter of execution for both navenibart and STAR-0310,” said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. “We are excited about the opportunity for navenibar.

Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress
businesswire.com19 September 2024 Sentiment: POSITIVE

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial navenibart ALPHA-STAR data at the upcoming European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, the Netherlands on September 26, 2024. Raffi Tachdjian, M.D., MPH, Associate Clinical Professor of Medicine and Pediatrics in the Division of Allergy and.

Astria Therapeutics, Inc. (ATXS) Q3 2023 Earnings Call Transcript
Seeking Alpha13 November 2023 Sentiment: POSITIVE

Astria Therapeutics, Inc. (NASDAQ:ATXS ) Q3 2023 Earnings Conference Call November 13, 2023 8:30 AM ET Company Participants Elizabeth Higgins - Investor Relations Jill Milne - Co Founder, CEO, President & Director Noah Clauser - CFO & Treasurer Christopher Morabito - Chief Medical Officer Andrea Matthews - Chief Business Officer Andrew Komjathy - Chief Commercial Officer Conference Call Participants Eun Yang - Jefferies Sam Slutsky - LifeSci Capital Hartaj Singh - Oppenheimer Farhana Sakloth - Ladenburg Joe Pantginis - H.C. Wainwright Operator Good morning and welcome to the Astria Therapeutics Quarter Three 2023 Corporate Update.

Astria Therapeutics to Present New STAR-0215 Data at the 2023 American College of Allergy, Asthma, And Immunology Annual Scientific Meeting
Business Wire03 November 2023 Sentiment: POSITIVE

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will share new STAR-0215 data in a poster presentation at the upcoming American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting in Anaheim, California on November 11, 2023 at 12:35pm PST. Dr. William Lumry, M.D., Clinical Professor of Internal Medicine at the Unive.

Astria Therapeutics strikes exclusive license agreement for dermatitis treatment portfolio
Proactive Investors12 October 2023 Sentiment: POSITIVE

Astria Therapeutics has inked a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio targeting the potential treatment of atopic dermatitis (AD) and other allergic and immunological diseases. The focus of the collaboration centers on the development of the lead candidate, STAR-0310, a monoclonal antibody OX40 antagonist utilizing YTE half-life extension technology.

Astria (ATXS) Rises 5% on Fast Track Tag for Angioedema Drug
Zacks Investment Research21 July 2023 Sentiment: POSITIVE

Astria (ATXS) gets FDA's fast track tag for its lead product candidate, STAR-0215, which is currently being evaluated in an early-mid-stage study to treat hereditary angioedema. The stock rises 5%.

Astria: Biotech To Watch With Proof Of Concept Established For HAE
Seeking Alpha24 April 2023 Sentiment: POSITIVE

Astria: Biotech To Watch With Proof Of Concept Established For HAE.

What type of business is Astria Therapeutics?

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

What sector is Astria Therapeutics in?

Astria Therapeutics is in the Healthcare sector

What industry is Astria Therapeutics in?

Astria Therapeutics is in the Biotechnology industry

What country is Astria Therapeutics from?

Astria Therapeutics is headquartered in United States

When did Astria Therapeutics go public?

Astria Therapeutics initial public offering (IPO) was on 25 June 2015

What is Astria Therapeutics website?

https://www.astriatx.com

Is Astria Therapeutics in the S&P 500?

No, Astria Therapeutics is not included in the S&P 500 index

Is Astria Therapeutics in the NASDAQ 100?

No, Astria Therapeutics is not included in the NASDAQ 100 index

Is Astria Therapeutics in the Dow Jones?

No, Astria Therapeutics is not included in the Dow Jones index

When was Astria Therapeutics the previous earnings report?

No data

When does Astria Therapeutics earnings report?

The next expected earnings date for Astria Therapeutics is 04 March 2025